CARR EDWARD 4

What Happened Edward Carr, Chief Accounting Officer of Dianthus Therapeutics (DNTH), was granted a stock option award for 55,000 shares on February 3, 2026. The Form 4 reports the acquisition price as $0.00 (derivative award) and a reported value of $0.00 for the grant. The award is a stock option (derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-03 (reported on Form 4 filed 2026-02-04). Transaction code: A (award/grant).
• Amount: 55,000 shares underlying a stock option award; reported acquisition price $0.00; total reported value $0.00.
• Vesting: The shares underlying the option will vest in equal monthly installments over four years after January 1, 2026, subject to continued service (per footnote).
• Shares owned after the transaction: not specified in this filing.
• Filing timeliness: Filed next business day (no late filing indicated).

Context This was a compensation-related option grant that vests over time; the options were not exercised or sold and therefore do not represent immediate market buying or selling. Such awards are common for executive retention and incentive alignment and do not, by themselves, indicate a near-term trading signal.